Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel (Q37743510)

22 August 2017

1 reference

title

Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel (English)

1 reference

22 August 2017

0 references

1 reference

1

Fausto Petrelli

1 reference

22 August 2017

3

Sandro Barni

1 reference

22 August 2017

2

Karen Borgonovo

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 June 2010

1 reference

Expert Opinion on Pharmacotherapy

22 August 2017

published in

1 reference

22 August 2017

volume

11

1 reference

22 August 2017

issue

8

1 reference

22 August 2017

page(s)

1413-1432

1 reference

Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517/14656561003796562

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003796562

Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003796562

Novel formulations of taxanes: a review. Old wine in a new bottle?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003796562

Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003796562

Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003796562

Novel markers for poor prognosis in head and neck cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003796562

Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003796562

Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003796562

Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003796562

Taxanes as primary chemotherapy for early breast cancer: meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003796562

Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003796562

Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003796562

Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003796562

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003796562

A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003796562

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003796562

nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003796562

The biology of caveolae: lessons from caveolin knockout mice and implications for human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003796562

Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003796562

Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003796562

Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003796562

Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003796562

An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003796562

Caveolae: mining little caves for new cancer targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003796562

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003796562

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003796562

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656561003796562

10.1517/14656561003796562

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference